Sinopharm Group 15on Stock Earnings Per Share
| X2S1 Stock | EUR 12.20 0.20 1.67% |
SINOPHARM GROUP 15ON fundamentals help investors to digest information that contributes to SINOPHARM GROUP's financial success or failures. It also enables traders to predict the movement of SINOPHARM Stock. The fundamental analysis module provides a way to measure SINOPHARM GROUP's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SINOPHARM GROUP stock.
SINOPHARM |
SINOPHARM GROUP 15ON Company Earnings Per Share Analysis
SINOPHARM GROUP's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current SINOPHARM GROUP Earnings Per Share | 1.77 X |
Most of SINOPHARM GROUP's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SINOPHARM GROUP 15ON is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, SINOPHARM GROUP 15ON has an Earnings Per Share of 1.77 times. This is 78.85% lower than that of the Healthcare sector and 58.04% higher than that of the Medical Distribution industry. The earnings per share for all Germany stocks is 43.27% higher than that of the company.
SINOPHARM Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SINOPHARM GROUP's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SINOPHARM GROUP could also be used in its relative valuation, which is a method of valuing SINOPHARM GROUP by comparing valuation metrics of similar companies.SINOPHARM GROUP is currently under evaluation in earnings per share category among its peers.
SINOPHARM Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Shares Outstanding | 624.13 M | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 7.03 X | |||
| Revenue | 546.15 B | |||
| Gross Profit | 44.05 B | |||
| EBITDA | 23.5 B | |||
| Net Income | 7.87 B | |||
| Cash And Equivalents | 34.36 B | |||
| Cash Per Share | 55.05 X | |||
| Total Debt | 86.79 B | |||
| Debt To Equity | 0.93 % | |||
| Current Ratio | 1.29 X | |||
| Book Value Per Share | 105.05 X | |||
| Earnings Per Share | 1.77 X | |||
| Number Of Employees | 113.23 K | |||
| Beta | 0.76 | |||
| Market Capitalization | 7.05 B | |||
| Annual Yield | 0.05 % | |||
| Last Dividend Paid | 0.75 |
About SINOPHARM GROUP Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SINOPHARM GROUP 15ON's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SINOPHARM GROUP using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SINOPHARM GROUP 15ON based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in SINOPHARM Stock
SINOPHARM GROUP financial ratios help investors to determine whether SINOPHARM Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SINOPHARM with respect to the benefits of owning SINOPHARM GROUP security.